Symbols / BIIB $190.07 +2.22% Biogen Inc.

Healthcare • Drug Manufacturers - General • United States • NMS
BIIB Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
About

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Fundamentals
Scroll to Statements
Market Cap 27.89B Enterprise Value 30.13B Income 1.29B Sales 9.89B Book/sh 124.36 Cash/sh 26.00
Dividend Yield — Payout 0.00% Employees 7500 IPO — P/E 21.60 Forward P/E 11.92
PEG 3.80 P/S 2.82 P/B 1.53 P/C — EV/EBITDA 8.36 EV/Sales 3.05
Quick Ratio 1.70 Current Ratio 2.68 Debt/Eq 36.47 LT Debt/Eq — EPS (ttm) 8.80 EPS next Y 15.94
EPS Growth — Revenue Growth -7.10% Earnings 2026-04-29 ROA 6.14% ROE 7.39% ROIC —
Gross Margin 78.95% Oper. Margin 19.64% Profit Margin 13.07% Shs Outstand 146.76M Shs Float 146.28M Short Float 3.37%
Short Ratio 3.96 Short Interest — 52W High 202.41 52W Low 115.25 Beta 0.16 Avg Volume 1.24M
Volume 1.33M Target Price $209.36 Recom Buy Prev Close $185.95 Price $190.07 Change 2.22%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$209.36
Mean price target
2. Current target
$190.07
Latest analyst target
3. DCF / Fair value
$243.08
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$190.07
Low
$150.00
High
$275.00
Mean
$209.36

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-22 up UBS Neutral → Buy $225
2026-04-20 up Wells Fargo Equal-Weight → Overweight $250
2026-04-14 up Piper Sandler Neutral → Overweight $214
2026-04-13 main Citigroup Neutral → Neutral $190
2026-04-13 main Truist Securities Hold → Hold $189
2026-04-10 main Morgan Stanley Equal-Weight → Equal-Weight $200
2026-04-02 main HC Wainwright & Co. Buy → Buy $237
2026-04-01 main Canaccord Genuity Buy → Buy $245
2026-04-01 main Oppenheimer Outperform → Outperform $275
2026-03-17 main HSBC Reduce → Reduce $150
2026-02-23 main Freedom Broker Hold → Hold $185
2026-02-20 init Barclays — → Equal-Weight $185
2026-02-10 main Wedbush Neutral → Neutral $187
2026-02-09 main JP Morgan Neutral → Neutral $230
2026-02-09 main Canaccord Genuity Buy → Buy $230
2026-02-09 main BMO Capital Market Perform → Market Perform $196
2026-02-09 main TD Cowen Buy → Buy $215
2026-02-09 main Citigroup Neutral → Neutral $215
2026-02-09 main RBC Capital Outperform → Outperform $233
2026-02-09 main Guggenheim Buy → Buy $246
News
RSS: Latest BIIB news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-01 GODBOUT SEAN Officer — 181 — —
2026-02-12 MURPHY NICOLE Officer — 3 $195.04 $585
2026-02-09 SINGHAL PRIYA Officer — 2,660 $199.83 $531,548
2026-02-06 MURPHY NICOLE Officer — 8,725 — —
2026-02-06 KEENEY ADAM JAMES Officer — 5,080 — —
2026-02-06 GROGAN JANE Officer — 3,258 — —
2026-02-06 GODBOUT SEAN Officer — 1,079 — —
2026-02-06 GREGORY GINGER Officer — 7,183 — —
2026-02-06 ALEXANDER SUSAN H Officer — 9,046 — —
2026-02-06 KRAMER ROBIN C. Chief Financial Officer — 5,003 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
9,890.60
+2.22%
9,675.90
-1.62%
9,835.60
-3.32%
10,173.40
Operating Revenue
9,890.60
+2.22%
9,675.90
-1.62%
9,835.60
+1.52%
9,688.30
Cost Of Revenue
2,404.20
+4.06%
2,310.40
-8.80%
2,533.40
+11.20%
2,278.30
Reconciled Cost Of Revenue
2,139.30
+2.66%
2,083.90
-8.57%
2,279.20
+7.22%
2,125.80
Gross Profit
7,486.40
+1.64%
7,365.50
+0.87%
7,302.20
-7.51%
7,895.10
Operating Expense
5,017.40
-1.33%
5,085.10
-6.77%
5,454.50
+9.24%
4,993.20
Research And Development
1,778.60
-10.19%
1,980.30
-19.02%
2,445.40
+9.61%
2,231.10
Selling General And Administration
2,433.60
+1.24%
2,403.70
-5.73%
2,549.70
+6.08%
2,403.60
Other Operating Expenses
290.20
+14.07%
254.40
+16.27%
218.80
+3056.76%
-7.40
Total Expenses
7,421.60
+0.35%
7,395.50
-7.42%
7,987.90
+9.85%
7,271.50
Operating Income
2,469.00
+8.27%
2,280.40
+23.42%
1,847.70
-36.33%
2,901.90
Total Operating Income As Reported
—
—
—
—
EBITDA
2,603.90
-7.97%
2,829.50
+38.80%
2,038.50
-53.21%
4,356.80
Normalized EBITDA
3,398.60
+9.40%
3,106.50
+18.60%
2,619.40
-25.15%
3,499.50
Reconciled Depreciation
779.90
+15.85%
673.20
+36.05%
494.80
-4.55%
518.40
EBIT
1,824.00
-15.41%
2,156.30
+39.68%
1,543.70
-59.78%
3,838.40
Total Unusual Items
-794.70
-186.90%
-277.00
+52.32%
-580.90
-167.76%
857.30
Total Unusual Items Excluding Goodwill
-794.70
-186.90%
-277.00
+52.32%
-580.90
-167.76%
857.30
Special Income Charges
-746.40
-412.29%
-145.70
+39.11%
-239.30
-120.45%
1,170.10
Other Special Charges
611.30
+596.24%
87.80
+328.29%
20.50
-97.76%
917.00
Impairment Of Capital Assets
52.90
0.00
0.00
—
Restructuring And Mergern Acquisition
82.20
+41.97%
57.90
-73.54%
218.80
+380.51%
-78.00
Net Income
1,292.90
-20.79%
1,632.20
+40.57%
1,161.10
-61.89%
3,046.90
Pretax Income
1,556.50
-18.34%
1,906.00
+46.98%
1,296.80
-63.90%
3,591.80
Net Non Operating Interest Income Expense
-142.50
+22.00%
-182.70
-717.23%
29.60
+118.82%
-157.30
Interest Expense Non Operating
267.50
+6.87%
250.30
+1.38%
246.90
+0.12%
246.60
Net Interest Income
-142.50
+22.00%
-182.70
-717.23%
29.60
+118.82%
-157.30
Interest Expense
267.50
+6.87%
250.30
+1.38%
246.90
+0.12%
246.60
Interest Income Non Operating
125.00
+84.91%
67.60
-75.55%
276.50
+209.63%
89.30
Interest Income
125.00
+84.91%
67.60
-75.55%
276.50
+209.63%
89.30
Other Income Expense
-770.00
-301.67%
-191.70
+66.98%
-580.50
-168.52%
847.20
Other Non Operating Income Expenses
24.70
-71.04%
85.30
+21225.00%
0.40
+103.96%
-10.10
Gain On Sale Of Security
-48.30
+63.21%
-131.30
+61.56%
-341.60
-9.21%
-312.80
Gain On Sale Of Business
—
0.00
0.00
-100.00%
1,505.40
Tax Provision
263.60
-3.73%
273.80
+102.37%
135.30
-78.62%
632.80
Tax Rate For Calcs
0.00
+17.89%
0.00
+38.13%
0.00
-40.91%
0.00
Tax Effect Of Unusual Items
-134.59
-238.23%
-39.79
+34.13%
-60.41
-140.04%
150.88
Net Income Including Noncontrolling Interests
1,292.90
-20.79%
1,632.20
+40.53%
1,161.50
-60.78%
2,961.60
Net Income From Continuing Operation Net Minority Interest
1,292.90
-20.79%
1,632.20
+40.57%
1,161.10
-61.89%
3,046.90
Net Income From Continuing And Discontinued Operation
1,292.90
-20.79%
1,632.20
+40.57%
1,161.10
-61.89%
3,046.90
Net Income Continuous Operations
1,292.90
-20.79%
1,632.20
+40.53%
1,161.50
-60.78%
2,961.60
Minority Interests
0.00
0.00
+100.00%
-0.40
-100.47%
85.30
Normalized Income
1,953.01
+4.47%
1,869.41
+11.17%
1,681.59
-28.15%
2,340.48
Net Income Common Stockholders
1,292.90
-20.79%
1,632.20
+40.57%
1,161.10
-61.89%
3,046.90
Diluted EPS
8.79
-21.38%
11.18
+40.28%
7.97
-61.81%
20.87
Basic EPS
8.83
-21.23%
11.21
+39.78%
8.02
-61.74%
20.96
Basic Average Shares
146.50
+0.62%
145.60
+0.62%
144.70
-0.41%
145.30
Diluted Average Shares
147.10
+0.82%
145.90
+0.21%
145.60
-0.27%
146.00
Diluted NI Availto Com Stockholders
1,292.90
-20.79%
1,632.20
+40.57%
1,161.10
-61.89%
3,046.90
Amortization
515.00
+15.29%
446.70
+85.66%
240.60
-34.24%
365.90
Amortization Of Intangibles Income Statement
515.00
+15.29%
446.70
+85.66%
240.60
-34.24%
365.90
Depreciation Amortization Depletion Income Statement
515.00
+15.29%
446.70
+85.66%
240.60
-34.24%
365.90
Depreciation And Amortization In Income Statement
515.00
+15.29%
446.70
+85.66%
240.60
-34.24%
365.90
Earnings From Equity Interest Net Of Tax
—
0.00
0.00
-100.00%
2.60
Gain On Sale Of PPE
—
0.00
0.00
-100.00%
503.70
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
29,439.50
+4.96%
28,049.30
+4.49%
26,844.80
+9.33%
24,554.10
Current Assets
8,974.10
+20.35%
7,456.80
+8.71%
6,859.30
-29.94%
9,791.20
Cash Cash Equivalents And Short Term Investments
3,815.70
+60.66%
2,375.00
+126.21%
1,049.90
-78.54%
4,892.80
Cash And Cash Equivalents
3,008.50
+26.67%
2,375.00
+126.21%
1,049.90
-69.29%
3,419.30
Other Short Term Investments
807.20
0.00
0.00
-100.00%
1,473.50
Receivables
1,867.00
-0.10%
1,868.80
-11.01%
2,100.00
-1.70%
2,136.40
Accounts Receivable
1,867.00
-0.10%
1,868.80
-11.01%
2,100.00
-1.70%
2,136.40
Gross Accounts Receivable
1,870.00
-0.05%
1,871.00
-11.01%
2,102.40
-1.70%
2,138.70
Allowance For Doubtful Accounts Receivable
-3.00
-36.36%
-2.20
+8.33%
-2.40
-4.35%
-2.30
Inventory
2,168.10
-11.88%
2,460.50
-2.65%
2,527.40
+87.99%
1,344.40
Raw Materials
—
—
—
413.20
Work In Process
—
—
—
751.90
Finished Goods
—
—
—
200.40
Other Current Assets
1,123.30
+49.28%
752.50
-36.34%
1,182.00
-16.62%
1,417.60
Total Non Current Assets
20,465.40
-0.62%
20,592.50
+3.04%
19,985.50
+35.38%
14,762.90
Net PPE
3,320.80
-6.13%
3,537.70
-5.15%
3,729.70
+0.73%
3,702.50
Gross PPE
6,252.00
+0.70%
6,208.50
+1.24%
6,132.20
+4.50%
5,868.20
Accumulated Depreciation
-2,931.20
-9.75%
-2,670.80
-11.17%
-2,402.50
-10.93%
-2,165.70
Properties
0.00
0.00
0.00
0.00
Land And Improvements
216.70
+7.07%
202.40
+0.00%
202.40
+0.00%
202.40
Buildings And Improvements
2,140.30
+8.99%
1,963.70
+22.63%
1,601.30
+0.53%
1,592.90
Machinery Furniture Equipment
3,323.00
+2.57%
3,239.80
+15.81%
2,797.40
+4.67%
2,672.50
Construction In Progress
163.10
-47.11%
308.40
-68.38%
975.40
+9.74%
888.80
Other Properties
265.40
-25.53%
356.40
-15.14%
420.00
+3.99%
403.90
Leases
143.50
+4.14%
137.80
+1.55%
135.70
+26.00%
107.70
Goodwill And Other Intangible Assets
15,669.60
-3.10%
16,170.10
+10.89%
14,582.20
+91.89%
7,599.10
Goodwill
6,491.10
+0.19%
6,478.90
+4.18%
6,219.20
+8.18%
5,749.00
Other Intangible Assets
9,178.50
-5.29%
9,691.20
+15.88%
8,363.00
+352.03%
1,850.10
Investments And Advances
431.90
0.00
0.00
-100.00%
705.70
Other Investments
—
—
—
1,529.20
Non Current Deferred Assets
292.50
-9.78%
324.20
-65.09%
928.60
-24.28%
1,226.40
Non Current Deferred Taxes Assets
292.50
-9.78%
324.20
-65.09%
928.60
-24.28%
1,226.40
Other Non Current Assets
750.60
+33.92%
560.50
-24.77%
745.00
-51.28%
1,529.20
Total Liabilities Net Minority Interest
11,182.70
-1.33%
11,333.30
-5.91%
12,045.40
+7.88%
11,165.70
Current Liabilities
3,349.40
-39.42%
5,528.80
+60.99%
3,434.30
+4.93%
3,272.80
Payables And Accrued Expenses
2,973.60
-12.65%
3,404.40
+15.43%
2,949.20
+38.44%
2,130.30
Payables
546.80
-43.77%
972.50
+47.19%
660.70
-12.07%
751.40
Accounts Payable
432.00
+1.84%
424.20
+5.18%
403.30
-17.95%
491.50
Current Accrued Expenses
2,426.80
-0.21%
2,431.90
+6.27%
2,288.50
+65.97%
1,378.90
Pensionand Other Post Retirement Benefit Plans Current
375.80
+0.00%
375.80
+12.15%
335.10
-15.29%
395.60
Total Tax Payable
114.80
-79.06%
548.30
+113.01%
257.40
-0.96%
259.90
Current Debt And Capital Lease Obligation
—
1,748.60
+1065.73%
150.00
—
Current Debt
—
1,748.60
+1065.73%
150.00
—
Other Current Borrowings
—
1,748.60
+1065.73%
150.00
—
Other Current Liabilities
—
—
838.40
+12.25%
746.90
Total Non Current Liabilities Net Minority Interest
7,833.30
+34.95%
5,804.50
-32.59%
8,611.10
+9.10%
7,892.90
Long Term Debt And Capital Lease Obligation
6,577.20
+34.73%
4,881.70
-32.09%
7,188.20
+8.68%
6,614.00
Long Term Debt
6,286.80
+38.26%
4,547.20
-33.01%
6,788.20
+8.08%
6,281.00
Long Term Capital Lease Obligation
290.40
-13.18%
334.50
-16.38%
400.00
+20.12%
333.00
Non Current Deferred Liabilities
507.60
+166.46%
190.50
-70.32%
641.80
+91.75%
334.70
Non Current Deferred Taxes Liabilities
507.60
+166.46%
190.50
-70.32%
641.80
+91.75%
334.70
Other Non Current Liabilities
748.50
+2.21%
732.30
-6.25%
781.10
-17.27%
944.20
Stockholders Equity
18,256.80
+9.22%
16,716.00
+12.95%
14,799.40
+10.46%
13,397.90
Common Stock Equity
18,256.80
+9.22%
16,716.00
+12.95%
14,799.40
+10.46%
13,397.90
Capital Stock
0.10
+0.00%
0.10
+0.00%
0.10
+0.00%
0.10
Common Stock
0.10
+0.00%
0.10
+0.00%
0.10
+0.00%
0.10
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
170.60
+0.64%
169.52
+0.49%
168.70
+0.54%
167.80
Ordinary Shares Number
146.80
+0.74%
145.72
+0.57%
144.90
+0.63%
144.00
Treasury Shares Number
23.80
+0.00%
23.80
+0.00%
23.80
+0.00%
23.80
Additional Paid In Capital
863.10
+51.58%
569.40
+88.23%
302.50
+312.69%
73.30
Retained Earnings
20,552.70
+6.71%
19,259.80
+9.26%
17,627.60
+7.05%
16,466.50
Gains Losses Not Affecting Retained Earnings
-182.00
-33.63%
-136.20
+11.39%
-153.70
+6.79%
-164.90
Treasury Stock
2,977.10
+0.00%
2,977.10
+0.00%
2,977.10
+0.00%
2,977.10
Minority Interest
—
—
0.00
+100.00%
-9.50
Other Equity Adjustments
-182.00
-33.63%
-136.20
+11.39%
-153.70
+6.79%
-164.90
Total Equity Gross Minority Interest
18,256.80
+9.22%
16,716.00
+12.95%
14,799.40
+10.54%
13,388.40
Total Capitalization
24,543.60
+15.43%
21,263.20
-1.50%
21,587.60
+9.70%
19,678.90
Working Capital
5,624.70
+191.74%
1,928.00
-43.71%
3,425.00
-47.46%
6,518.40
Invested Capital
24,543.60
+6.66%
23,011.80
+5.86%
21,737.60
+10.46%
19,678.90
Total Debt
6,577.20
-0.80%
6,630.30
-9.65%
7,338.20
+10.95%
6,614.00
Net Debt
3,278.30
-16.39%
3,920.80
-33.41%
5,888.30
+105.76%
2,861.70
Capital Lease Obligations
290.40
-13.18%
334.50
-16.38%
400.00
+20.12%
333.00
Net Tangible Assets
2,587.20
+373.93%
545.90
+151.34%
217.20
-96.25%
5,798.80
Tangible Book Value
2,587.20
+373.93%
545.90
+151.34%
217.20
-96.25%
5,798.80
Available For Sale Securities
431.90
—
—
705.70
Inventories Adjustments Allowances
—
—
—
-21.10
Investmentin Financial Assets
431.90
0.00
0.00
-100.00%
705.70
Other Inventories
—
—
—
-21.10
Preferred Shares Number
0.01
+0.00%
0.01
+0.00%
0.01
+0.00%
0.01
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
2,204.60
-23.33%
2,875.50
+85.85%
1,547.20
+11.77%
1,384.30
Cash Flow From Continuing Operating Activities
2,204.60
-23.33%
2,875.50
+85.85%
1,547.20
+11.77%
1,384.30
Net Income From Continuing Operations
1,292.90
-20.79%
1,632.20
+40.53%
1,161.50
-60.78%
2,961.60
Depreciation Amortization Depletion
779.90
+15.85%
673.20
+36.05%
494.80
-4.55%
518.40
Depreciation
272.80
-4.85%
286.70
+12.79%
254.20
-6.68%
272.40
Amortization Cash Flow
507.10
+31.20%
386.50
+60.64%
240.60
-2.31%
246.30
Depreciation And Amortization
779.90
+15.85%
673.20
+36.05%
494.80
-4.55%
518.40
Amortization Of Intangibles
507.10
+31.20%
386.50
+60.64%
240.60
-2.31%
246.30
Other Non Cash Items
456.90
-12.00%
519.20
+70.73%
304.10
-9.31%
335.30
Stock Based Compensation
290.80
-0.14%
291.20
+10.22%
264.20
+3.97%
254.10
Provisionand Write Offof Assets
—
—
—
—
Asset Impairment Charge
60.80
+1.00%
60.20
0.00
-100.00%
119.60
Deferred Tax
361.60
+328.72%
-158.10
+48.30%
-305.80
-81.38%
-168.60
Deferred Income Tax
361.60
+328.72%
-158.10
+48.30%
-305.80
-81.38%
-168.60
Operating Gains Losses
19.30
+50.78%
12.80
-95.38%
277.10
+115.87%
-1,745.80
Gain Loss On Investment Securities
19.30
-80.97%
101.40
-63.41%
277.10
+4.21%
265.90
Gain Loss On Sale Of PPE
0.00
+100.00%
-88.60
0.00
+100.00%
-503.70
Change In Working Capital
-1,057.60
-581.44%
-155.20
+76.08%
-648.70
+27.14%
-890.30
Change In Receivables
42.10
-78.32%
194.20
+242.50%
56.70
+125.49%
-222.40
Changes In Account Receivables
102.70
-53.80%
222.30
+262.64%
61.30
+130.14%
-203.40
Change In Inventory
-64.70
+76.37%
-273.80
-109.17%
-130.90
+59.12%
-320.20
Change In Payables And Accrued Expense
171.10
+595.53%
24.60
+112.20%
-201.60
-77.78%
-113.40
Change In Accrued Expense
171.10
+595.53%
24.60
+112.20%
-201.60
-77.78%
-113.40
Change In Other Working Capital
-1,206.10
-1103.69%
-100.20
+73.13%
-372.90
-59.15%
-234.30
Investing Cash Flow
-1,371.10
-71.56%
-799.20
+80.51%
-4,101.00
-360.12%
1,576.60
Cash Flow From Continuing Investing Activities
-1,371.10
-71.56%
-799.20
+80.51%
-4,101.00
-360.12%
1,576.60
Net PPE Purchase And Sale
-153.80
-0.07%
-153.70
+44.51%
-277.00
-180.92%
342.30
Purchase Of PPE
-153.80
-0.07%
-153.70
+44.51%
-277.00
-15.27%
-240.30
Sale Of PPE
—
0.00
0.00
-100.00%
582.60
Capital Expenditure
-235.40
+34.57%
-359.80
-15.54%
-311.40
-28.04%
-243.20
Net Investment Purchase And Sale
-1,178.60
-914.51%
144.70
-93.87%
2,359.70
+960.54%
222.50
Purchase Of Investment
-1,258.30
0.00
+100.00%
-5,140.70
-49.07%
-3,448.50
Sale Of Investment
79.70
-44.92%
144.70
-98.07%
7,500.40
+104.31%
3,671.00
Net Business Purchase And Sale
0.00
+100.00%
-668.00
+89.12%
-6,138.00
-719.81%
990.30
Purchase Of Business
0.00
+100.00%
-1,074.80
+84.48%
-6,926.10
0.00
Gain Loss On Sale Of Business
—
0.00
0.00
+100.00%
-1,505.40
Net Intangibles Purchase And Sale
-81.60
+30.55%
-117.50
-241.57%
-34.40
-1086.21%
-2.90
Purchase Of Intangibles
-81.60
+60.41%
-206.10
-499.13%
-34.40
-1086.21%
-2.90
Net Other Investing Changes
42.90
+1012.77%
-4.70
+58.41%
-11.30
-146.31%
24.40
Financing Cash Flow
-301.90
+55.83%
-683.50
-557.80%
149.30
+108.54%
-1,747.30
Cash Flow From Continuing Financing Activities
-301.90
+55.83%
-683.50
-557.80%
149.30
+108.54%
-1,747.30
Net Issuance Payments Of Debt
-16.90
+97.40%
-650.00
-447.04%
187.30
+118.69%
-1,002.20
Issuance Of Debt
1,733.10
0.00
-100.00%
997.20
0.00
Repayment Of Debt
-1,750.00
-169.23%
-650.00
+19.74%
-809.90
+19.19%
-1,002.20
Long Term Debt Issuance
1,733.10
0.00
-100.00%
997.20
0.00
Long Term Debt Payments
-1,750.00
-169.23%
-650.00
+19.74%
-809.90
+19.19%
-1,002.20
Net Long Term Debt Issuance
-16.90
+97.40%
-650.00
-447.04%
187.30
+118.69%
-1,002.20
Net Common Stock Issuance
—
0.00
0.00
+100.00%
-750.00
Common Stock Payments
—
0.00
0.00
+100.00%
-750.00
Repurchase Of Capital Stock
—
0.00
0.00
+100.00%
-750.00
Proceeds From Stock Option Exercised
-10.00
+68.05%
-31.30
+29.35%
-44.30
-2231.58%
-1.90
Net Other Financing Charges
-275.00
-12400.00%
-2.20
-134.92%
6.30
-7.35%
6.80
Changes In Cash
531.60
-61.83%
1,392.80
+157.92%
-2,404.50
-298.13%
1,213.60
Effect Of Exchange Rate Changes
101.90
+250.52%
-67.70
-292.88%
35.10
+163.02%
-55.70
Beginning Cash Position
2,375.00
+126.21%
1,049.90
-69.29%
3,419.30
+51.20%
2,261.40
End Cash Position
3,008.50
+26.67%
2,375.00
+126.21%
1,049.90
-69.29%
3,419.30
Free Cash Flow
1,969.20
-21.72%
2,515.70
+103.57%
1,235.80
+8.30%
1,141.10
Interest Paid Supplemental Data
264.10
+7.62%
245.40
-2.70%
252.20
-3.92%
262.50
Income Tax Paid Supplemental Data
864.00
+143.31%
355.10
-52.06%
740.70
+182.17%
262.50
Earnings Losses From Equity Investments
—
0.00
0.00
+100.00%
-2.60
Sale Of Business
0.00
-100.00%
406.80
-48.38%
788.10
-20.42%
990.30
Sale Of Intangibles
0.00
-100.00%
88.60
0.00
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category